Research Interests

Causal inference and observational studies; Risk prediction; Clinical Biostatistics; Treatment Selection.

Selected Methods Publications [* indicates corresponding/senior author]

1. Chen Y, Yu M* (2023). Randomized phase II selection design with order constrained strata. Biometrics. In press. [Distinguished Student Paper Award of the International Biometrics Society, ENAR Region, 2023]

2. Chen R, Chen G*, Yu M* (2023). Entropy balancing for causal generalization with target sample summary information. Biometrics. In press.

3. Chen R, Huling J, Chen G*, Yu M* (2023). Robust sample weighting to facilitate individualized treatment rule learning for a target population. Biometrika. In press.

4. Chen R, Chen G*, Yu M* (2023). A generalizability score for aggregate causal effects. Biostatistics. 24 (2): 309-26.

5. Park C, Chen G, Yu M, Kang H (2023). Minimum resource threshold policy under partial interference. Journal of the American Statistical Association. In press.

6. Liang M and Yu M* (2022). A semiparametric approach to model effect modification.  Journal of the American Statistical Association. 117 (538): 752-64. [ASA Biometrics Section Travel Award - 2017]

7. Huling J, Yu M* (2022). Sufficient dimension reduction for populations with structured heterogeneity.  Biometrics. 78(4):1626-1638

8. Wang T, Chen R, Liu W, Yu M* (2022). Structure-preserving integrated analysis for risk stratification with application to cancer staging. Biostatistics. 23 (3): 990-1006.

9. Huling J, Yu M (2021). Subgroup identification using the personalized Package. Journal of Statistical Software. 98(5), 1–60. [Number of downloads of this R package.]

10. Chen R and Yu M* (2021). Tailored optimal post-treatment surveillance for cancer recurrence. Biometrics. 77: 942– 955. [ASA Biometrics Section Travel Award - 2018]

11. Yu M, Kuang C, Huling J, Smith M (2021). Diagnosis-group-specific transitional care program recommendations for thirty-day rehospitalization reduction. Annals of Applied Statistics. 15(3): 1478-1498.

12. Huling J, Yu M*, O’Malley J (2019). Instrumental variable based estimation under the semiparametric accelerated failure time model. Biometrics. 75(2):516-527.

13. Ye T and Yu M* (2018). A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect. Biometrics. 74(4):1292-1300. [The Charles B. Sampson Poster Award - 2018]

14. Chen S, Tian L, Cai T, Yu M* (2017). A general statistical framework for subgroup identification and comparative treatment scoring. Biometrics, 73(4): 1199-209. [One of the most downloaded articles in Biometrics between 2016-2018 according to Wiley’s e-service]

15. McDaniel LS, Yu M*, Chappell R* (2016). Sample size under the additive hazards model. Clinical Trials: Journal of the Society for Clinical Trials, 13(2): 188-98. [Finalist, Society for Clinical Trials Thomas Chalmers Student Paper Award, 2014]

16. Xu Y, Yu M*, Zhao Y, Li Q, Wang S, Shao J (2015). Regularized outcome weighted subgroup identification for differential treatment effects. Biometrics, 71, 645-53. [The John Van Ryzin Award of the International Biometrics Society, ENAR Region, 2014]

17. Yu M. (2013). Adjusted regression estimation for time-to-event data with differential measurement error. Biometrika. 100(3): 757-63.

18. Yu M and Nan B (2010). Regression calibration in semiparametric accelerated failure time models. Biometrics, 66, 405-414.

19. Nan B, Kalbfleish JD, Yu M (2009). Asymptotic Theory for the semiparametric accelerated failure time model with missing data. Annals of Statistics, 37, 2531-76.

20. Yu M, Taylor JMG, Sandler HM (2008). Individual prediction in prostate cancer studies using a joint longitudinal-survival-cure model. Journal of the American Statistical Association, 103, 178-187. [Distinguished Student Paper Award of the International Biometrics Society, ENAR Region, 2003]

Selected Collaboration Publications

1. Liu Y, Yu M*, LaMantia JN, Lobo JM, Boutilier JJ, Liu Ya, Brennan MB (2023). Associations between specialty care and improved outcomes among patients with diabetic foot ulcers. Plos One. In press. [Equal contribution as co-first author]

2. Schumacher JR, Neuman HB, Yu M et al (2022). Surveillance imaging vs symptomatic recurrence detection and survival in stage II-III breast cancer (AFT-01), JNCI: Journal of the National Cancer Institute. 114(10):1371-1379. [This journal's impact score: 14]

3. Martini A, Yu M, et al. (2022). Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: the potential impact of informative censoring. Cancer. 128(15):2892-2897.

4. Yu M, Coller, RJ, Kind AJH (2020). Tailoring patient care to reduce hospital admissions for cerebral palsy patients. Developmental Medicine & Child Neurology. 62 (8):889. [Invited commentary]

5. Zhao SG, Yu M, Spratt DE, Chang SL, Feng FY, Kim MM, Speers CW, Carlson BL, Mladek AC, Lawrence TS, Sarkaria JN, Wahl DR (2019). Xenograft-based platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. Neuro-Oncology. 21(9):1141-1149. [This journal's impact score: 10.1]

6. Smith MA, Vaughan-Sarrazin MS, Yu M, Wang X, Nordby P, Vogeli C, Jaffery J, Metlay JP (2019). The importance of health insurance claims data in creating learning health systems: Evaluating care for high-need high-cost patients using the National Patient-Centered Clinical Research Network (PCORNet). Journal of the American Medical Informatics Association. 26(11):1305-1313.

7. Imperiale TF, Yu M, Monahan PO, Stump TE, Tabbey R, Glowinski E, Ransohoff DF (2017). Risk of advanced neoplasia using the national cancer institute’s colorectal cancer risk assessment tool. Journal of National Cancer Institute, 109 (1). [This journal's impact score: 14]

8. Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Speers C, Den RB, Dicker AP, Freedland SJ, Karnes RJ, Ross A, Schaeffer EM, Davicioni E, and Feng FY (2016). The Development and validation of a 24-gene predictor of response to post-operative radiation therapy in prostate cancer: a matched retrospective analysis. Lancet Oncology, 17(11): 1612-1620. [This journal's impact score: 54]

9. Kind AJH, Jencks S, Brock J, Yu M, Bartels C, Ehlenback W, Greenberg C and Smith M (2014). Neighborhood socioeconomic disadvantage and 30 day rehospitalizations: an analysis of medicare data. Annals of Internal Medicine, 161(11):765-74. [This journal's impact score: 51]

10. Wang L, Zhao Z, Meyer MB, Saha S, Yu M, Guo A, Wisinski KB, Huang W, Cai W, Pike JW, Yuan M, Ahlquist P, Xu W (2014). CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis. Cancer Cell, 25(1): 21-36. [This journal's impact score: 39]

11. Fisher WI, Johnson AK, Elkins GR, Otte JL, Burns DS, Yu M, Carpenter JS (2013). Risk factors, pathophysiology, and treatment of hot flashes in cancer. CA: a Cancer Journal for Clinicians, 63(3):167-92. [This journal's impact score: 580]

12. Carpenter JS, Wu J, Burns DS, Yu M (2012). Perceived Control and Hot Flashes in Treatment-seeking Breast Cancer Survivors and Menopausal Women. Cancer Nursing, 35(3): 195-202. [Cover article]

13. Zhao Z, Yu M, Crabb D, Xu Y, Liangpunsakul S (2011). Ethanol-Induced Alterations in Fatty Acid-Related Lipids in Serum and Tissues in Mice. Alcoholism: Clinical and Experimental Research, 35(2): 229-234.

14. Nelson RP, Yu M, Schwartz JE, et al (2010). Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia. Bone Marrow Transplantation, 45(8): 1300-8.

15. Hahn NM, Zon RT, Yu M, Ademuyiwa FO, Jones T, Dugan W, Whalen C, Shanmugam R, Skaar T, Sweeney CJ (2009). A phase II study of Pemetrexed as second-line chemotherapy for the treatment of metastatic castrate resistant prostate cancer (CRPC). Annals of Oncology, 20(12): 1971-6. [This journal's impact score: 51.8]

16. Taylor JMG, Yu M, Sandler HM (2005). Individualized predictions of disease progression following radiation therapy for prostate cancer. Journal of Clinical Oncology, 23, 816-825. [This journal's impact score: 50.7]

Search PubMed for other publications by Menggang Yu

Courses Taught

1. Theory and Methods of Survival Analysis (Biostat/Stat 741)

2. Introduction to Causal Inference (Regular Course at TU Dortmund, Germany)

3. Causal Inference and Subgroup Analysis (Short Course)

4. Clinical Trial Biostatistics (Short Course)

5. Longitudinal Data Analysis (Short Course)

6. Introduction to Survival Analysis (Short Course)

Full CV (updated 1/1/2024)